Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013

Published:2014-01-24 Issue:7 Volume:55 Page:1609-1617
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

da Silva Antonio,Kronthaler Ulrich,Koppenburg Vera,Fink Martin,Meyer Ines,Papandrikopoulou Anastassia,Hofmann Matthias,Stangler Thomas,Visser Jan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.843090

Reference29 articles.

1. Therapeutic antibodies for human diseases at the dawn of the twenty-first century

2. Trends in US approvals: new biopharmaceuticals and vaccines

3. The economic pressures for biosimilar drug use in cancer medicine

4. Worldwide experience with biosimilar development

5. The State of the Art in the Development of Biosimilars

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars;Journal of Pharmaceutical and Biomedical Analysis;2023-09

2. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon^®) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma;Therapeutic Advances in Hematology;2023-01

3. Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review;The AAPS Journal;2021-12-20

4. Biosimilar Monoclonal Antibodies in Latin America;Biosimilars [Working Title];2021-12-07

5. Need for a risk-based control strategy for managing glycosylation profile for biosimilar products;Expert Opinion on Biological Therapy;2021-09-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3